Millendo Therapeutics (NASDAQ:MLND) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a sell rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

MLND has been the topic of several other research reports. Jefferies Financial Group began coverage on Millendo Therapeutics in a research note on Wednesday, March 13th. They issued a buy rating and a $22.00 price objective on the stock. ValuEngine lowered Welbilt from a hold rating to a sell rating in a report on Wednesday, June 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $23.25.

Shares of NASDAQ:MLND opened at $10.67 on Wednesday. Millendo Therapeutics has a 52-week low of $6.77 and a 52-week high of $17.34. The business has a 50 day moving average price of $13.36. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02.

Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.08). As a group, equities research analysts predict that Millendo Therapeutics will post -3.25 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Worth Venture Partners LLC purchased a new stake in Millendo Therapeutics during the fourth quarter worth $206,000. BlackRock Inc. purchased a new stake in Millendo Therapeutics during the fourth quarter worth $203,000. Private Advisors LLC lifted its holdings in Millendo Therapeutics by 9.1% during the first quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after buying an additional 1,279 shares during the period. Geode Capital Management LLC purchased a new stake in Millendo Therapeutics during the fourth quarter worth $113,000. Finally, Tibra Equities Europe Ltd purchased a new stake in Millendo Therapeutics during the first quarter worth $303,000. Institutional investors own 44.07% of the company’s stock.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Recommended Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.